Abstract
‘DARAPRIM’ [2 : 4-diamino-5-(-4′-chlorophenyl)-6-ethyl pyrimidine (50–63) ] has been described1 as having high antimalarial activity in laboratory infections of Plasmodium gallinaceum, Plasmodium berghei and Plasmodium cynomolgi. More recently, it has also been tried in the treatment and suppression of human malaria2. It has been shown that proguanil-resistant strains of the first two species are sensitive to ‘Daraprim’ and that ‘Daraprim’ resistance is not easily produced in P. gallinaceum infections3.
Similar content being viewed by others
Article PDF
References
Falco, E. A., Goodwin, L. G., Hitchings, G. H., Rollo, I. M., and Russell, P. B., Brit. J. Pharmacol., 6, 185 (1951).
Archibald, H. M., Brit. Med. J., 2, 821 (1951). McGregor, I. A., and Smith, D. A., Brit. Med. J., 1, 730 (1952). Goodwin, L. G., Brit. Med. J., 1, 732 (1952).
Rollo, I. M., Nature, 168, 332 (1951).
Goodwin, L. G., Nature, 164, 1133 (1949).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
ROLLO, I. ‘Daraprim’ Resistance in Experimental Malarial Infections. Nature 170, 415 (1952). https://doi.org/10.1038/170415a0
Issue Date:
DOI: https://doi.org/10.1038/170415a0
This article is cited by
-
Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance
Malaria Journal (2009)
-
Zur Wirkung des 2,4-diamino-5-P-chlorphenyl-6-�thyl-pyrimidins (Daraprim) auf das h�matopoetische System
Klinische Wochenschrift (1956)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.